Fig 1: Immunolocalization of PDGF-Rß, NG2, a-SMA, and CD146 in the human umbilical cord. Fluorescence imaging revealed a high incidence of PDGF-Rß-positive (a–c), NG2-positive (d–f), a-SMA-positive (g–i), and CD146-positive (j–l) cells in the perivascular region. Bar: 25 µm. The integrated optical density (IOD) values of positive staining in five randomly selected high power fields of view were counted. ***P < 0.001, versus WJ-MSCs. *P < 0.05, versus WJ-MSCs. ##P < 0.01, UCV-PSCs versus UCA-PSCs.
Fig 2: Tumor tissue immunodynamics and gene expression studies suggest immuno-priming by bevacizumab. Representative immunohistochemistry images of a CD8+ infiltration, b CD4+ infiltration, and c Treg infiltration in tumors from non-progressor and progressors patients (upper panels). The lower panels represent the geometric mean and standard deviation of the quantitation data from all available tumor biopsies. d The six analyzed tumors were negative for PD-L1 expression (applying the 1% boundary), regardless of experiencing benefit or not from the treatment combination. e Confocal imaging showing representative fields containing normalized blood vessels from a non-progression (the whole microvessel wall—CD31-positive endothelial cells—is covered by NG2-positive pericytes) and a progressor patient (who, in turn, displays vessel abnormality—lack of pericyte coverage and tortuous architecture). The chart represents the quantitative differences between the average percentage of microvessel wall covered by pericytes in non-progressors versus progressors; **P < 0.01. f Functionally representative GSEAs of the main regulated pathways in non-progressors’ tumors; NES, normalized enrichment score (the higher NES, the higher functional enrichment); both corrected (false discovery ratio (FDR)) and uncorrected P values are shown. g Same as in (f) for non-responders. h Further enriched GSEAs in responders and non-responders ranked by their NES; all of them with FDR < 0.001. Scalebars: a–c 20 µm; d 100 µm; e 25 µm
Fig 3: Phenotype and multidirectional differentiation potential of En-PSCs. a Immunofluorescence staining in human endometrium displayed CD146, CD31, PDGFRß, and a-SMA. The arrow showed En-PSCs. Scale bars, 25 µm. b En-PSCs (CD146+CD34-CD45-CD56-CD144-) were sorted by flow cytometry. c–m Flow cytometry analysis of immune-markers in En-PSCs. n–p En-PSCs expressed PDGFRß, NG2, and a-SMA. Scale bars, 25 µm. q Intracellular lipid droplet induced from En-PSCs were detected by Oil red O staining. Scale bars, 50 µm. r Calcified nodule stained with Alizarin red S indicated that En-PSCs differentiated to osteogenic lineage. Scale bars, 50 µm. Neural-like differentiation was confirmed by immunofluorescence staining with anti-NSE antibody (s) and anti-NF-M antibody (t). Scale bars, 50 µm
Supplier Page from Abcam for Anti-NG2 antibody [EPR9195]